Innovative pharmaceutical companies' overseas licensing collaborations remain active, and the Hong Kong Connect Innovative Drugs ETF Harvest (520970) is expected to continue benefiting

腾讯新闻 - 财经
2026.04.01 02:59
portai
I'm LongbridgeAI, I can summarize articles.

The overseas licensing cooperation of innovative pharmaceutical companies continues to be active, and the Harvest CSI Hong Kong Connect Innovative Drugs ETF (520970) is expected to benefit continuously. On the morning of April 1, 2026, the CSI Hong Kong Connect Innovative Drugs Index rose by 4.91%, with constituent stock LEPU BIO-B increasing by 11.24%. In the first three months of 2026, the total value of foreign licensing transactions for innovative drugs in China has exceeded USD 60 billion. The NMPA has launched the "Spring Rain Action" for the transformation of clinical innovation achievements in medical devices, supporting the industrialization of innovative results. The valuation of the pharmaceutical sector is 29.3 times PE, lower than the historical average, and the market's attention to innovative pharmaceutical companies with core technology platforms has increased

Source: 腾讯新闻 - 财经 The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2026 Longbridge｜Disclaimer